The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy

• ClinicalTrials.gov Identifier: NCT03423849
• Recruitment Status: Unknown
• First Posted: February 6, 2018
• Last Update Posted: February 6, 2018
• Sponsor: Zhiyong Yu
• Information provided by (Responsible Party): Zhiyong Yu, Shandong Cancer Hospital and Institute

Study Description

Brief Summary:

Worldwide, breast cancer is the most incident and prevalent cancer among women. Despite advances in the treatment of advanced breast cancer (ABC) during the past decade, adjuvant systemic therapy has yield little progression for such patients. ABC remains an incurable disease, responsible for approximate 40,000 deaths annually and a median life expectancy of no more than 3 years. The NCCN guidelines clearly define routine adjuvant chemotherapy regimens for the early breast cancer, however, for the patients with recurrence and metastasis, the choice of treatment options is not clear. In this trial, we choose the patients with disease progression who received anthracycline and taxane adjuvant chemotherapy after surgery. The patients received vinorelbine and gemcitabine (NG) or vinorelbine and platinum (NP) regiments for 6 cycles. Then the patients with complete response (CR), partly response (PR) and stable disease(SD) will be assigned to 3 groups, one group will receive the original regiment for 3 cycles to maintain treatment, one group will receive the vinorelbine for 6 cycles, the other group will receive the capecitabine for 6 cycles. Trasuzumab will be used to patients if HER-2 positive. Endocrine therapy will be used if the hormone receptors positive after the chemotherapy. The primary endpoint is to assess disease-free survival (DFS), the secondary endpoint is to assess the overall survival (OS).

Condition or disease	Intervention/treatment	Phase
Breast Cancer; Chemotherapy Effect; Disease-free Survival	Drug: Vinorelbine; Drug: Gemcitabine; Drug: Cisplatin; Drug: Capecitabine	Phase 2; Phase 3

Detailed Description:

The trial is designed to help us to choose the maintain treatment regiment for the patients with effective first-line salvage therapy. After inorelbine and gemcitabine (NG) or vinorelbine and platinum (NP) regiments for 6 cycles, patients will be assess the effect of treatment. As for the patients with complete response (CR), partly response (PR) and stable disease(SD), the investigators will randomly assign them to receive 3 cycles of original regiment, or 6 cycles of vinorelbine, or 6 cycles of capecitabine. Trasuzumab will be used to patients if HER-2 positive. Endocrine therapy will be used if the hormone receptors positive after the chemotherapy. The effectiveness of therapy will be estimated after the maintain therapy. The first two years the patient was prescribed every 3 months to review the disease, then review the disease every six months. The primary endpoint is to assess disease-free survival (DFS), the secondary endpoint is to assess the overall survival (OS).

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 200 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Prospective Randomized Controlled Study of the Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy
• Estimated Study Start Date: February 8, 2018
• Estimated Primary Completion Date: February 8, 2020
• Estimated Study Completion Date: February 8, 2020

Arms and Interventions

Arm	Intervention/treatment
Experimental: The original program (NG/NP); Vinorelbine injection 25mg/m2 on day 1 and day 8, Gemcitabine injection 1250mg/m2 on day1 and day 8,every 3 weeks for 3 cycles（for the patients who used the NG salvage therapy） or Vinorelbine injection 25mg/m2 on day 1 and day 8,Cisplatin injection 25mg/m2 on day1,every 3 weeks for 3 cycles（for the patients who used the NP salvage therapy ）	Drug: Vinorelbine; 25mg/m2,day 1 and day 8, every 3 weeks; Other Name: Anhydmvinblastine; Drug: Gemcitabine; 1250mg/m2,day 1 and day 8, every 3 weeks; Other Name: Gemcel; Drug: Cisplatin; 25mg/m2,day 1,every 3 weeks; Other Name: cisplatinum
Experimental: One of the original program (N); Vinorelbine injection,25mg/m2 on day 1 and day 8,every 3 weeks for 6 cycles. or, Vinorelbine oral 60mg/m2 on day 1,every week for 6 cycles.	Drug: Vinorelbine; 25mg/m2,day 1 and day 8, every 3 weeks; Other Name: Anhydmvinblastine
Experimental: Capecitabine monotherapy; Capecitabine oral 1250mg/m2,bid,for 6 cycles	Drug: Capecitabine; 1250mg/m2,day 1 to day 14, every 3 weeks; Other Name: XELODA

Outcome Measures

Primary Outcome Measures :

1. Disease-free survival (DFS) [ Time Frame: 5 years ]
   To determine the percentage of disease-free survival (DFS) for the The original program (NG/NP) or One of the original program (N) or Capecitabine monotherapy

Secondary Outcome Measures :

1. Overall survival (OS) [ Time Frame: 5 years ]
   To determine the percentage of Overall survival (OS) for the The original program (NG/NP) or One of the original program (N) or Capecitabine monotherapy

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• All patients were required to give written informed consent.
• Patients with distant metastasis who primary received anthracycline and taxane adjuvant chemotherapy after surgery.
• After inorelbine and gemcitabine (NG) or vinorelbine and platinum (NP) regiments for 6 cycles,patients were assessed the effect of treatment. As for the patients with complete response (CR), partly response (PR) and stable disease(SD).
• Have normal cardiac functions by echocardiography
• ECOG scores are ≤ 0-1.
• Patients are disposed to practice contraception during the whole trial.
• The results of patients' blood tests are as follows:

Hb ≥ 90 g/L WBC ≥ 3.0×109/L Plt ≥ 100×109/L Neutrophils ≥ 1.5×109/L ALT and AST ≤ 2.5 times of normal upper limit. TBIL ≤ 1.5 times of normal upper limit. Creatinine ≤ 1.5 times of normal upper limit.

Exclusion Criteria:

• Have other cancers at the same time or have the history of other cancers in recent five years, excluding the controlled skin basal cell carcinoma or skin squamous cell carcinoma or carcinoma in situ of cervix.
• Active infections.
• Severe non-cancerous diseases.

Contacts and Locations

Contacts

Contact: Zhiyong Yu, PhD; 86-13355312277; drzhiyongyu@aliyun.com

Contact: Zhaoyun Liu, MD; 86-17865123967; liuzhaoyun99@163.com

Sponsors and Collaborators

Zhiyong Yu

Investigators

• Study Chair: Zhiyong Yu, PhD; Shandong Cancer Hospital and Institute
• Principal Investigator: Zhaoyun Liu, MD; Shandong Cancer Hospital and Institute

More Information

• Responsible Party: Zhiyong Yu, Director of the Breast Surgery Ⅰ, Shandong Cancer Hospital and Institute
• ClinicalTrials.gov Identifier: NCT03423849
• Other Study ID Numbers: ShandongCHI-04
• First Posted: February 6, 2018
• Last Update Posted: February 6, 2018
• Last Verified: February 2018

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Breast Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Gemcitabine; Cisplatin; Capecitabine; Vinorelbine; Antineoplastic Agents; Antimetabolites, Antineoplastic; Antimetabolites; Molecular Mechanisms of Pharmacological Action; Antiviral Agents; Anti-Infective Agents; Enzyme Inhibitors; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Antineoplastic Agents, Phytogenic; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators